Kornimate/medical-research-clean huggingface dataset:
long-term follow-up of patients enrolled in the early treatment diabetic retinopathy study (etdrs)

Conditions: Diabetic Retinopathy

Summary: patients enrolled in the original early treatment diabetic retinopathy study at the clinical center at johns hopkins wilmer eye institute will be invited for a follow-up visit at the national eye institute. visual function will be assessed with manifest refraction and standardized visual acuity measurement. the progression of retinopathy will be evaluated by ocular exam and fundus photography. a brief medical history will be obtained. the goal of this study is to evaluate the long-term results of patients whose diabetic retinopathy was treated with different strategies of scatter and/or focal laser photocoagulation.

to evaluate the long-term clinical course and prognosis of diabetic retinopathy treated with different strategies of scatter and/or focal laser photocoagulation in patients enrolled in the early treatment diabetic retinopathy study (etdrs).

Eligibility criteria:
patient was originally enrolled in the early treatment diabetic retinopathy study at the johns hopkins wilmer eye institute. patient not previously enrolled are not eligible.

Keywords: diabetic retinopathy long-term visual outcome photocoagulation j. h. wilmer eye institute
metabolic radiotherapy after complete resection of liver metastases in patient with digestive neuroendocrine tumor

Conditions: Digestive Neuroendocrine Tumors; Metabolic Radiotherapy; Resection; Liver Metastases

Summary: teravect is a phase iii randomized study of patients with digestive neuroendocrine tumors after complete surgical resection of liver metastases treated with in111-pentetreotide-based adjuvant radiotherapy. in this study, targeted radionuclide therapy is used at an earlier stage of the disease.the objective is to target residual tumor cells and/or micrometastases which escaped surgical resection. given the poor prognosis associated with recurrence, this treatment should prevent relapse.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent, * age ≥ 18 years, * patients with well differenciated digestive neuroendocrine tumors and liver metastases, for whom a complete surgical resection of liver metastases and of the primary tumor was performed, in 1 or 2 times, * immunohistochemical confirmation of neuroendocrine tumors with who 2010 grading specification and ki67 determined of the surgical specimen, * ecog performance status (ps) 0-1, * adequate hematological status: platelets \>100000/mm3, hemoglobin \>10g/dl, * adequate clearance creatinine \>60 ml/min, * adequate liver function: total serum bilirubin \<1.5x upper limit of normal (uln), transaminases \<3 x uln, * grade of in111-pentetreotide uptake ≥ 2 (scored according to the krenning et al scale.: more intense than physiological liver uptake), * treatment started within 14 weeks after surgical resection, * men and women are required to use adequate birth control measures during the course of the study and for a period of 12 months after the last administration of study drug. female patients with childbearing potential must have a negative serum pregnant test (β-hcg) within 7 days before starting study treatment, * life expectancy \>6 months * registration with the national health care system (cmu included for france) exclusion criteria: * history of previous or second cancer or progressive cancer occurring within 5 years prior to inclusion, except for basal cell or squamous cell carcinoma, * patients with known sensibility or hypersensibility to in111- pentetreotide or any component of the treatment drug, * pregnant or breast-feeding women without adequate birth control measures, * patient with known medical history of psychological or psychiatric disorders that may affect patient participation in study due to lack of cooperation or loss of autonomy preventing hospitalization and initiation of study treatment (in good radiation protection conditions), * treatment with any investigational drug within 28 days prior to study entry, * patient protected by law (tutelage or guardianship).
non-interventional study with ra-223 dichloride assessing overall survival and effectiveness predictors for mcrpc patients in a real life setting in germany

Conditions: Prostatic Neoplasms, Castration-Resistant

Summary: this observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic castration resistant prostate cancer (mcrpc) patients receiving radium- 223 under real life conditions. in addition, time to next tumor treatment (ttnt), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.


Eligibility criteria:
inclusion criteria: * male patients diagnosed with castration resistant adenocarcinoma of the prostate (crpc) with symptomatic bone metastases without known visceral metastases * decision to initiate treatment with radium-223 was made as per investigator's routine treatment practice exclusion criteria: -patients participating in an investigational program with interventions outside of routine clinical practice and also in all non-interventional studies focusing on radium- 223-dichloride.

Keywords: mcrpc
testing a cbt program for anxiety in teenagers with autism: a feasibility study

Conditions: Anxiety; Autism

Summary: the objective is to investigate the feasibility of a newly developed manualised group cognitive behavioural therapy (cbt) programme for anxiety in 15 teenagers (aged 13-17 years) with autism spectrum disorder (asd). our aim is to focus primarily on acceptability and compliance with the program with some investigation of treatment effects on anxiety diagnosis and anxiety symptoms.


Eligibility criteria:
inclusion criteria: * fulfil the diagnostic criteria for one or more anxiety diagnoses on the anxiety disorders interview schedule for dsm-iv: parent \& child interview schedule (adis c/p) * obtained a diagnosis of asd according to the international classification of diseases, 10th edition (icd 10) exclusion criteria: * low intellectual functioning (\<70) * active psychosis * untreated hyperkinetic disorder * inability to speak danish * inability to leave the home * inability to attend a group setting * inability to meet for treatment caused by other psychiatric disorders.

Keywords: cbt anxiety autism feasibility teenagers
in patients with hip dysplasia, mid-term lower extremities and spine after hip arthroplasty natural course

Conditions: Total Hip Arthroplasty

Summary: patients with developmental hip dysplasia often present to the outpatient clinic in adulthood with hip pain due to progressive hip osteoarthritis. however, they may have complaints such as limping, lumbar lordosis, lower back pain, and leg length difference. today, the best treatment option for these patients is hip arthroplasty. hip arthroplasty causes a high rate of functional improvement and pain relief. according to the hip arthroplasty technique applied, improvement in lameness, leg length difference and spinal curvatures is expected. the aim of our study is to show the change in postoperative spine and lower extremity curvatures after hip arthroplasty in patients with advanced developmental hip dislocation.

developmental hip dysplasia (ddh) describes the spectrum of anatomical changes in the acetabulum and proximal femur; these can cause limping, lower back pain, lumbar lordosis, and leg length variation. ddh is the main cause of degenerative arthritis of the hip and valgus deformity of the knee. the best treatment option for ddh is total hip arthroplasty (tha). during tha, the distorted anatomy of the acetabulum and proximal femur poses great difficulties. additionally, the soft tissue can be released and the femur can be shortened while correcting the placement of the acetabulum to prevent neurological damage (sciatic nerve paralysis). postoperative evaluations focused on assessing joint function and alleviating preoperative clinical symptoms. some studies have examined changes in lower extremity and knee alignment after tha in patients with ddh. in patients with ddh, tha may cause genu valgus deformity due to increased lower extremity length and q angle immediately after the operation. tha extends the lower extremity, affecting the patellofemoral joint and anterior knee pain. however, the long-term effects of tha on the alignment of the lower extremity are unclear, especially in patients with crowe type iii and iv ddh, which involves femoral shortening osteotomy. there are few studies examining changes in the knee and lower extremities as a result of tha in patients with ddh. the aim of this study is to evaluate the mid- and long-term alignment of the spine and lower extremity after tha with or without femoral shortening osteotomy in patients with unilateral ddh (crowe type iii-iv).

Eligibility criteria:
inclusion criteria: 1. patients with unilateral crowe type 3 hip dysplasia 2. patients with unilateral crowe type 4 hip dysplasia exclusion criteria: 1. patients with unilateral crowe type 1 hip dysplasia 2. patients with unilateral crowe type 2 hip dysplasia 3. history of previous surgery on the hip for which surgery is planned

Keywords: hip total hip arthroplasty developmental hip dysplasia
study on reflex response during temporary stimulation and inhibition of chemoreceptors of carotid bodies - a pilot study

Conditions: Heart Failure; Peripheral Chemoreceptor Hypersensitivity

Summary: the isolated response of the carotid bodies to local stimulation with adenosine has not been researched in humans. there are single reports indicating that intravenous administration of adenosine causes hyperventilation through activating the carotid bodies. adenosine will be injected intraarterially during invasive treatment (percutaneous carotid artery stenting, cas) or diagnostic (arteriography) procedures and their conduct will only slightly influence the standard scheme of the procedure.


Eligibility criteria:
inclusion criteria: * stenosis of one of the internal carotid arteries qualifying the patient to the procedure treatment (according to the esc 2011 or american heart association (aha) guidelines) or the necessity of the carotid artery arteriography, in order to verify the level of narrowing; * in the case of procedure treatment, patient's declaration to be treated by the percutaneous method; * stable clinical condition for at least 4 weeks prior to the inclusion in the study; * over 18 years of age; * ability to give and giving the informed consent to participate in the study. exclusion criteria: * bilateral significant carotid artery stenosis; * complete closure or critical constriction of either of the carotid arteries; * brain stroke or transient ischaemic attack (tia) within 6 months prior to the inclusion in the study; * unstable angina pectoris, coronary attack within 3 months prior to the inclusion in the study; * coronary revascularisation or clinically significant infection within 1 month prior to the inclusion in the study; * significant chronic neurological condition in medical history; * dipyridamole or theophyline-based medications taken by the patient; * bronchial asthma; * gold 3 or 4 chronic obstructive pulmonary disease (copd) in medical history; * second or third degree atrioventricular block, sick sinus syndrome, or an additional evident track of atrioventricular conducting; * advanced first degree atrioventricular block (pq \> 240 ms) * extension of the qtc interval \> 0.5 s; * grade 3 (esc) arterial hypertension; * previously stated oversensitivity to adenosine; * pregnancy; * patients undergoing haemodialysis or peritoneal dialysis at inclusion in the study; * undergone heart transplantation; * any significant, in the investigator's assessment, aberrations detected in additional tests, increasing the risk related to performing procedures predicted by the protocol; * lack of informed consent for the participation in the study; * stage iii (fontaine) obliterative arteriosclerosis of the lower limb and/or buerger's disease.
safety of donepezil in patients with dementia associated with cerebrovascular disease

Conditions: Dementia Associated With Cerebrovascular Disease

Summary: one year extension study following a previous double-blind study to evaluate safety of the drug

a one year extension study for patients who completed e2020-a001-319. patients will receive 5my donepezil daily for the first 8 weeks and will be assessed by the incidence of advere events, changes in physical exams, ecg and clinical lab determinations. the results will be assessed 6 timues during the year. after 8 week, the investigator may increase the dose to 10mg/day if the patient if the patients show satisfactory tolerability. six psychometric scales will also be evaluatd.

Eligibility criteria:
inclusion criteria: * must have completed previous study e2020-a001-319 exclusion criteria: * absence of a reliable caregiver * clinically significant medical condition * recent tia

Keywords: dementia stroke
emotional labor, physical labor and mental labor of hospice care nurses: a mixed-method study

Conditions: Hospitalism

Summary: hospice care is a nurse-led multidisciplinary team care that provides physical, mental, and social care to end-of-life patients. according to the who, the role of hospice nurses is addressing suffering involves taking care of issues beyond physical symptoms, to support patients and their caregivers. different from other disease care, hospice nurses face end-of-life patients and their families. as the primary nursing contact of a dying family, hospice nurses have a more intense and complex emotional experience. in china, with the improvement of human rights protection awareness, the nurse-patient relationship is particularly important, and the social requirements for nursing workers are also getting higher and higher. in addition, hospice nurses not only provide physical and psychological care to patients, but also provide comprehensive care to families of end-of-life patients. it is not just the mental work of learning expertise and dealing with emergency situations, and the physical labor of caring for large numbers of patients; but also requires emotional labor that has rarely been recognized before. when facing end-of-life patients and their families, it is particularly important to express appropriate emotions and pay emotional labor.


Eligibility criteria:
inclusion criteria: * the inclusion criteria were nurses working as registered nurses for 6 months or more. exclusion criteria: * nurses who were not directly involved in patient care (e.g., central sterile supply department nurses), and intern nurses were excluded.

Keywords: hospice advanced cancer palliative care nurse
efficacy of h2 receptor antagonist in prevention of thienopyridine-related peptic ulcer

Conditions: Peptic Ulcer

Summary: whether h2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.

the aim of the prospective, randomized study is investigate the efficacy of h2 receptor antagonist in prevention of thienopyridine-related peptic ulcer and gastrointestinal bleeding in patients with an ulcer history. we plan to enroll 236 thienopyridine (clopidogrel or ticlopidine) users with a peptic ulcer history who don't have baseline gastroduodenal ulcers at initial endoscopy . the patients will be randomly assigned to receive either (1) famotidine (40 mg qd) plus thienopyridine used previously or (2) placebo plus thienopyridine treatment alone for 6 months. the ulcer recurrence rate between the treatment gruops will be compared.

Eligibility criteria:
inclusion criteria: 1. the past history of gastroduodenal ulcer and underwent endoscopy for dyspeptic symptoms. 2. thienopyridine users without baseline gastroduodenal ulcer at initial endoscopy. 3. they are adult patients aged least 20 years of age. exclusion criteria: 1. they have a history of gastric or duodenal surgery other than oversewing of a perforation. 2. they require long-term treatment with non-steroidal anti-inflammatory drugs. 3. serious disease.

Keywords: histamine-2 receptor antagonist peptic ulcer thienopyridine prevention
a real-world study of toripalimab in chinese patients with lung cancer(thunder study)

Conditions: Lung Cancer

Summary: our project is going to clarify the efficacy and safety of toripalimab in lung cancer in the real world, and to evaluate the incidence of adverse events (aes) of special interest during toripalimab immunotherapy.

tumor immunotherapy, as another important treatment after surgical treatment, chemoradiotherapy and targeted therapy, has achieved great success and gradually become one of the standard treatment methods for tumors. toripalimab is the first chinese pd-1 inhibitor approved for the treatment of nasopharyngeal carcinoma, malignant melanoma, urothelial carcinoma, esophageal squamous cell carcinoma and non-small cell lung cancer. it has been widely used in clinical practice. several clinical studies have confirmed that it is safe and effective. in recent years, several clinical studies have reported that toripalimab alone or in combination can improve the response rate of cancer treatment and improve survival. the results of toripalimab research are mainly derived from rigorously designed randomized controlled trials (rcts), and the efficacy and safety in the real world still need to be further explored. real world studies, based on a large sample size, non-randomly select treatment measures according to the actual condition and wishes of patients, and pay attention to meaningful outcome treatment, which is closer to real clinical practice, without extrapolation difficulties, and has more clinical practical value. therefore, it is of great significance to carry out a real-world study to investigate the differences in the efficacy and adverse reactions of toripalimab immunotherapy in chinese lung cancer patients in order to better guide clinical practice, which also provides research direction and data support for further prospective studies.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * cytologically or histologically confirmed lung cancer. * complete clinical data. * indications for immunotherapy with toripalimab. exclusion criteria: * lack of patient key data. * refusal or uncooperation with the study.
respiratory muscle strength in volleyball players suffered from covid-19

Conditions: Covid19

Summary: in literature, there is no data evaluating respiratory functions in volleyball players during covid-19 pandemic. the aim of this study is to evaluate and compared pulmonary functions, respiratory muscle strength, body compositions and performance situations perceptions in female volleyball players with covid-19 and non-covid-19.


Eligibility criteria:
inclusion criteria: * having passed at least 30 days after the polymerase chain reaction (pcr) test turned negative * willing to participate in the study exclusion criteria: * having a history of chronic lung disease * unwilling to participate in the study

Keywords: respiratory muscles pulmonary functions
effect of low-dose interferon-alfa2a on peri-operative immune suppression

Conditions: Colon Cancer

Summary: the aim of this randomized double-blinded placebo-controlled phase 2 study is to determine efficacy of preoperative treatment with interferon-alfa2a in patients with pmmr colon cancer on perioperative immune suppression and infiltration of lymphocytes in the primary tumor.


Eligibility criteria:
inclusion criteria: * patients above 18 years of age. * patients diagnosed with pmmr colonic adenocarcinoma and scheduled for laparoscopic hemicolectomy. * asa class i-iii (classification of the american society of anesthesiology) exclusion criteria: * patients with childbearing potential without a negative pregnancy test before initiating study drug and / or non-acceptance to the use of contraceptive methods \* * ecog score function\> / = 3 * current liver or renal disease. * severe heart disease * previous depression diagnosed by a psychiatrist or in treatment with antidepressant * autoimmune disease. * uncontrolled thyroid disease. * patients who are or have recently (within 6 months) received treatment with immunosuppressive agents other than corticosteroid treatment. * epilepsy and / or other serious cns disorders. * patients that have undergone major surgery within one month before planned colon resection. * known hypersensitivity to recombinant interferon or auxiliary products of pegasys®. * spiral, pill, implant, transdermal patch, vaginal ring or depot injection. sterile / infertile subjects are exempt from the use of contraception. to be considered sterile or infertile must generally be surgical sterilization (vasectomy, bilateral tubectomy, hysterectomy or ovariectomy) or be postmenopausal, defined as absent menstruation for at least 12 months prior to study enrolment.
neoadjuvant immunotherapy in advanced nsclc

Conditions: Lung Cancer, Non-small Cell

Summary: a number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. this study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in nsclc. one such example would be to evaluate either single agent or an immunotherapy combination with chemotherapy. following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

a number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. this study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in nsclc. \[the power life sciences investigative team\](https://www.withpower.com) is running a study to evaluate either single agent or an immunotherapy combination with chemotherapy. patients can contact a site administrator via the information below, or enroll directly via \ https://www.withpower.com/trial/phase-4-2019-e67c1\ . following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

Eligibility criteria:
inclusion criteria: * \>= 18 years of age * informed consent is provided * histologically confirmed resectable non-small cell lung cancer with stage ii-iiia (tnm 8th edition) * eastern cooperative oncology group (ecog) performance status 0-1 * epidermal growth factor receptor (egfr) mutation negative and anaplastic lymphoma kinase (alk) translocation negative exclusion criteria: * egfr mutation positive and alk translocation positive * active central nervous system (cns) metastases * autoimmune diseases * inhaled or topical steroids, and adrenal replacement steroid doses \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease * patients with interstitial lung disease will not be included if they have symptomatic interstitial lung disease (ild) - grade 3-4 * women who are breast feeding or pregnant * sexually active women or men of childbearing potential who are not willing to use an effective contraceptive method during the study